Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature

Ferlay, 2013, Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, Eur J Cancer, 49, 1374, 10.1016/j.ejca.2012.12.027 Smith, 2000, Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database, J Urol, 164, 1964, 10.1016/S0022-5347(05)66929-7 Peinemann, 2011, Low-dose rate brachytherapy for men with localized prostate cancer, Cochrane Database Syst Rev, 7, 10.1002/14651858.CD008871.pub2 Wallner, 1996, Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma, J Clin Oncol, 14, 449, 10.1200/JCO.1996.14.2.449 Kotecha, 2013, Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer, Brachytherapy, 128, 44, 10.1016/j.brachy.2012.05.003 Salembier, 2007, Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy, Radiother Oncol, 83, 3, 10.1016/j.radonc.2007.01.014 Hoskin PJ1, 2013, GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update, Radiother Oncol, 107, 325, 10.1016/j.radonc.2013.05.002 Erickson, 2011, American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy, Int J Radiat Oncol Biol Phys, 79, 641, 10.1016/j.ijrobp.2010.08.046 Aluwini, 2012, High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-Year experience, Int J Radiat Oncol Biol Phys, 83 Alongi, 2013, Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: a review, Crit Rev Oncol Hematol., 88 Skowronek, 2010, Optimization and its influence on value of doses in HDR and PDR brachytherapy, Neoplasma, 57, 369 Skowronek, 2010, Values of biologically equivalent doses in healthy tissues: comparison of PDR and HDR brachytherapy techniques, Brachytherapy, 9, 165, 10.1016/j.brachy.2009.08.007 Martinez, 2002, Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer, Int J Radiat Oncol Biol Phys, 53 Pistis, 2010, External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology, Brachytherapy, 9, 15, 10.1016/j.brachy.2009.05.001 Joiner, 2009, 392 Cosset, 2013, Hypofractionnement en radiothérapie: l’éternel retour, Cancer Radiother, 17, 355, 10.1016/j.canrad.2013.06.027 Brenner, 2002, Direct evidence that prostate tumors show high sensitivity to fractionation [low α/β value], similar to late-responding normal tissue, Int J Radiat Oncol Biol Phys, 52, 6, 10.1016/S0360-3016(01)02664-5 Miralbell, 2012, Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β=1.4 [0.9–2.2]Gy, Int J Radiat Oncol Biol Phys, 82, e17, 10.1016/j.ijrobp.2010.10.075 Proust-Lima, 2011, Confirmation of a low α/β value for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics, Int J Radiat Oncol Biol Phys, 79, 195, 10.1016/j.ijrobp.2009.10.008 Kal, 2003, How low is the α/β ratio for prostate cancer?, Int J Radiat Oncol Biol Phys, 57, 1116, 10.1016/S0360-3016(03)01455-X Daşu, 2007, Is the α/β value for prostate tumours low enough to be safely used in clinical trials?, Clin Oncol (R Coll Radiol), 19, 289, 10.1016/j.clon.2007.02.007 De Bari, 2013, Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the young radiation oncologist meeting. Prostate cancer as a paradigm of multidisciplinary approach?. Highlights from the young radiation oncologist meeting, Tumori, 99, 637, 10.1177/030089161309900601 King, 2002, LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models, Brachytherapy, 1, 219, 10.1016/S1538-4721(02)00101-0 Orton, 2001, High-dose-rate brachytherapy may be radiobiologically superior to low-dose rate due to slow repair of late-responding normal tissue cells, Int J Radiat Oncol Biol Phys, 49, 183, 10.1016/S0360-3016(00)00810-5 Heemsbergen, 2014, Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival, Radiother Oncol, 110, 104, 10.1016/j.radonc.2013.09.026 Hennequin, 2010, Prostate cancer: doses and volumes of radiotherapy, Cancer Radioth, 14, 474, 10.1016/j.canrad.2010.07.229 Beckendorf, 2011, 70Gy vs. 80Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial, Int J Radiat Oncol Biol Phys, 80, 1056, 10.1016/j.ijrobp.2010.03.049 Zaorsky, 2013, Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer, Expert Rev Med Devices, 10, 751, 10.1586/17434440.2013.841347 Demanes, 2009, Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation, Am J Clin Oncol, 32, 342, 10.1097/COC.0b013e31818cd277 Sathya, 2005, Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate, J Clin Oncol, 23, 1192, 10.1200/JCO.2005.06.154 Khor, 2013, Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs. external beam radiation therapy alone for prostate cancer, Int J Radiat Oncol Biol Phys, 85, 679, 10.1016/j.ijrobp.2012.07.006 Galalae, 2004, Long-term outcome by risk factors using conformal high-dose-rate brachytherapy [HDR-BT] boost with or without neoadjuvant androgen suppression for localized prostate cancer, Int J Radiat Oncol Biol Phys, 58, 1048, 10.1016/j.ijrobp.2003.08.003 Aström, 2005, Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer, Radiother Oncol, 74, 157, 10.1016/j.radonc.2004.10.014 Mate, 1998, High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report, Int J Radiat Oncol Biol Phys, 41, 525, 10.1016/S0360-3016(98)00097-2 Dinges, 1998, High-dose rate interstitial with external beam irradiation for localized prostate cancer--results of a prospective trial, Radiother Oncol, 48, 197, 10.1016/S0167-8140(98)00054-1 Hiratsuka, 2004, Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer, Int J Radiat Oncol Biol Phys, 59, 684, 10.1016/j.ijrobp.2003.11.035 Hsu, 2010, Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321, Int J Radiat Oncol Biol Phys, 78, 751, 10.1016/j.ijrobp.2009.08.048 Demanes, 2005, High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results, Int J Radiat Oncol Biol Phys, 61, 1306, 10.1016/j.ijrobp.2004.08.014 Hoskin, 2012, Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer, Radiother Oncol., 103, 217, 10.1016/j.radonc.2012.01.007 Mohammed, 2012, Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer, Int J Radiat Oncol Biol Phys, 82, 204, 10.1016/j.ijrobp.2010.10.009 Grills, 2004, High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds, J Urol, 171, 1098, 10.1097/01.ju.0000113299.34404.22 Demanes, 2011, High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer, Int J Radiat Oncol Biol Phys, 81, 1286, 10.1016/j.ijrobp.2010.10.015 Zamboglou, 2013, High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results, Int J Radiat Oncol Biol Phys, 85, 672, 10.1016/j.ijrobp.2012.07.004 Rogers, 2012, High dose brachytherapy as monotherapy for intermediate risk prostate cancer, J Urol, 187, 109, 10.1016/j.juro.2011.09.050 Hoskin, 2012, High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence, Int J Radiat Oncol Biol Phys, 82, 1376, 10.1016/j.ijrobp.2011.04.031 Martinez, 2010, High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer, Am J Clin Oncol, 33, 481, 10.1097/COC.0b013e3181b9cd2f Ghadjar, 2009, Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy, Brachytherapy, 8, 45, 10.1016/j.brachy.2008.09.004 Barkati, 2012, High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial, Int J Radiat Oncol Biol Phys, 82, 1889, 10.1016/j.ijrobp.2010.09.006 Komiya, 2013, Early quality of life outcomes in patients with prostate cancer managed by high-dose-rate brachytherapy as monotherapy, Int J Urol, 20, 185, 10.1111/j.1442-2042.2012.03125.x Prada, 2012, High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results, Brachytherapy, 11, 105, 10.1016/j.brachy.2011.05.003 Yoshioka, 2014, Monotherapeutic high-dose-rate brachytherapy for prostate cancer: a dose reduction trial, Radiother Oncol, 110, 114, 10.1016/j.radonc.2013.10.015 Ghilezan, 2012, High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data, Int J Radiat Oncol Biol Phys, 83, 927, 10.1016/j.ijrobp.2011.05.001 Tharp, 2008, Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer, Brachytherapy, 7, 231, 10.1016/j.brachy.2008.03.003 Jo, 2012, Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy—preliminary results, BJU Int, 109, 835, 10.1111/j.1464-410X.2011.10519.x Lee, 2007, Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience, Int J Radiat Oncol Biol Phys, 67, 1106, 10.1016/j.ijrobp.2006.10.012 Chen, 2013, Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes, Int J Radiat Oncol Biol Phys, 86, 324, 10.1016/j.ijrobp.2013.01.027 Yamada, 2014, Zelefsky MJ.A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy, Brachytherapy, 13, 111, 10.1016/j.brachy.2013.11.005 http://www.clinicaltrials.gov/ct2/results?term=HDR+prostate. [Accessed online on 26.05.14].